Pharma - Q3FY23 - Earnings Preview
Low single-digit growth in the US market (due to intense competition) and low double-digit growth in the India business after Covid-19 business has...
302 Views
Pharma Q2fy23 Preview
The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%
148 Views
Axis Research Scorecard Report - Sep 22
Axis Top Picks basket reported a resilient performance with an astounding return of 143% since its inception, notably beating an 84% return...
290 Views
Abbott India Ltd - Key Therapies Report Robust Sales Improvement
AIL reported revenue growth of 7.1% YoY in Q1FY23 (vs. our expectations of 8% YoY), outpacing the IPM* growth of 2.0% (IPM: Indian Pharma Industry,...
302 Views
Pharma Q4FY22 Preview: Cost Pressure and Pricing Erosion Compress Margins
We expect companies under our Pharma coverage to report high singledigit growth (6.2% YoY), primarily driven by Injectable and Generic segment.
258 Views